What was meant to be a carefree weekend getaway turned into a harrowing ordeal for two young women from Melbourne, Florida, ...

A man from Eloy has become the first rattlesnake bite case treated by Banner Health in 2025. Officials with the health system ...

Disclaimer: The content presented here is for entertainment purposes only and does not guarantee the authenticity or accuracy of the information. The content may contain elements of fiction, ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

Their mother, Stephanie Brink, was able to escape the structure. (Their father ... Related: Mom Who Died Saving Her 2 Kids in House Fire Receives Posthumous Medal: 'Everyone Is Calling Her a Hero' ...

home. Their mother, Stephanie Brink, was able to escape the structure. (Their father, Ron, died from cancer in 2022, per Gant News.) At the time, several first responders were dispatched and ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

chemotherapy with a median progression-free survival of more than one year Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu to an earlier HR-positive treatment setting and broadens the patient ...

Since 2022, Enhertu has been approved in the U.S. to treat advanced breast tumors expressing “low,” but still detectable, levels of the HER2 protein. With its new decision, the agency widened ...

He has vowed to “transform the structure, strategy, funding and culture” of the MCB, and for the organisation to be a “unifying force” in the Muslim community. In his inaugural address ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." Researchers ...